Oxidation of LDL (OxLDL) renders it immunogenic and both a humoral and cell-mediated response occurs. The overall goal of this unit is to explore the role of the immune response to OxLDL, with emphasis on the humoral immunity that occurs in human populations. We will measure the autoantibody titers to epitopes of oxidized LDL in plasma of human subjects already enrolled in a variety of well established epidemiologic studies containing both men and women of various ethnic backgrounds. We will determine the relationship of the titers to clinical and anatomical measures of atherosclerosis and to a variety of risk factors such as age, smoking hyperlipidemia, gender, diabetes and/or ethnic background. In particular, we will determine if the titer of these antibodies is predictive of future clinical events and whether interventions, such as hypolipidemic or antioxidant therapy in humans and animal models will alter autoantibody titers. We will determine if immune complexes with LDL are found in plasma in animals and humans, and if there relate to the extent of atherosclerosis. We will utilize sensitive immunological techniques to determine if epitopes of OxLDL found in atherosclerotic lesions are also present on circulating LDL and if the levels of these differ in various patient populations. We will clone and characterize naturally occurring monoclonal antibodies to epitopes of OxLDL derived from apo E- derived from apo E-deficient with extensive atherosclerosis. Because these mice have not been immunized exogenously, the monoclonal antibodies to OxLDL presumably define epitopes actually formed in vivo. These antibodies will be used to characterize in detail a spectrum of epitopes present in OxLDL and, in turn, these defined antigens will be used as immunogens in Unit 3 to determine if immunization of mice with these epitopes will augment the humoral immune response and ameliorate atherosclerosis, as was previously observed in WHHL rabbits immunized with autologous malondialdehyde-modified LDL. Finally, together with Unit 2, we will also utilize these antibodies to define the epitopes on OxLDL that bind to the various OxLDL receptors present on macrophages. Thus, these studies should provide both clinical and basic information that will help to better understand the role of the immune response to oxidation of LDL, and may provide useful diagnostic tools and outline new therapeutic options.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
1P50HL056989-02
Application #
6273234
Study Section
Project Start
1998-04-01
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Pechlaner, Raimund; Willeit, Peter; Summerer, Monika et al. (2015) Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident cardiovascular disease. Arterioscler Thromb Vasc Biol 35:229-36
Huang, Wendy; Ghisletti, Serena; Saijo, Kaoru et al. (2011) Coronin 2A mediates actin-dependent de-repression of inflammatory response genes. Nature 470:414-8
Wan, Yihong; Evans, Ronald M (2010) Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol 44:135-42
Chou, Meng-Yun; Fogelstrand, Linda; Hartvigsen, Karsten et al. (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119:1335-49
Bergmark, Claes; Dewan, Asheesh; Orsoni, Alexina et al. (2008) A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49:2230-9
Liguori, Antonio; D'Armiento, Francesco P; Palagiano, Antonio et al. (2008) Maternal C-reactive protein and developmental programming of atherosclerosis. Am J Obstet Gynecol 198:281.e1-5
Li, A C; Glass, C K (2007) Use of mouse models to evaluate roles of nuclear receptors and their ligands in the pathogenesis and treatment of atherosclerosis. Curr Drug Targets 8:1273-87
Kiechl, Stefan; Willeit, Johann; Mayr, Manuel et al. (2007) Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27:1788-95
Ghisletti, Serena; Huang, Wendy; Ogawa, Sumito et al. (2007) Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 25:57-70
Damas, Jan K; Smith, Camilla; Oie, Erik et al. (2007) Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 27:614-20

Showing the most recent 10 out of 120 publications